Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Seraing – page 59

1 425 clinical trials in Seraing, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Seraing at a glance
1 425
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 425 trials in Seraing

Open in trial search

Hypertension

Not recruiting

Study on Lorundrostat for Patients with Uncontrolled and Resistant Hypertension

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Lorundrostat
  • Sponsor:Mineralys Therapeutics Inc.

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Obesity+1

Not recruiting

Efficacy and safety of oral semaglutide for weight loss in adults with overweight or obesity

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Obesity

Not recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enicepatide
  • Sponsor:F. Hoffmann-La Roche AG

Rheumatoid arthritis

Not recruiting

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Sponsor:Amgen Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Seraing

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) optimization in patients with chronic usage patterns. The research evaluates various deprescribing strategies for individuals without clear long-term PPI indications.

  • Functional Dyspepsia Management
  • Gastroesophageal Reflux Treatment
  • Heartburn Control Studies

This innovative trial compares on-demand medication use and alternative therapeutic approaches with traditional tapering methods, aiming to establish optimal deprescribing protocols in primary care settings.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.